News

Cogenics developed the proprietary genotyping service called the Pain Research Panel, which enables the investigation of key target genes involved in pain as well as those that mediate

As a result, Cambridge, Massachusetts-based Alnylam has rescinded all grants of its intellectual property related to current and future Merck development programs, including the partnership’s former co-development programs.

The nine-month opposition period for the patent expired on August 8, 2007. The patent also has been granted in several other countries outside of Europe. Intellect Neurosciences is

A post-hoc subgroup analysis of women at higher fracture risk showed that bazedoxifene 20mg reduced the incidence of non-vertebral fracture by 52% relative to placebo. With regard to

GlaxoSmithKline signed the deal with the Defense Threat Reduction Agency of the US Department of Defense, and said that it will provide supplemental staff and cover other program

The data was presented in late-breaking sessions at the Interscience Conference on Antimicrobial Agents and Chemotherapy meeting. This newly approved CCR5 antagonist – the first new class of

Ceftobiprole also was found to clinically cure more than 90% of patients who had infections caused by Staphylococcus aureus, including patients with complicated skin infections due to PVL-positive

The State of Maryland is contributing $100,000 of the $232,000 per year to the project at University of Maryland, Baltimore (UMB), with an agreement to provide second year

The two Phase III trials are anticipated to each enroll approximately 300 patients. AZ-004 is being developed through Symphony Allegro, a product development collaboration formed between Alexza and